Heterozygous mutations in bone morphogenetic protein receptor 2 (BMPR2) have been reported in 53–86% of hereditary pulmonary arterial hypertension cases and in 14–35% of idiopathic PAH patients (Gräf et al., 2018). Here, BMPR2 is linked to pulmonary arterial hypertension.